Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta‐analysis.
Summary: What is known and objective: The FDA has provided recommendations for aripiprazole use in CYP2D6 poor metabolizers (PMs); however, PMs make up <1% of the Asian population and no recommendation has been provided for intermediate metabolizers (IMs), who comprise a considerable proportion of t...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 44; no. 2; pp. 163 - 174 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research systematic review tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Apr2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |